[HTML][HTML] Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC)
C Faivre-Finn, DR Spigel, S Senan, C Langer… - Lung Cancer, 2021 - Elsevier
Introduction The PACIFIC trial demonstrated that durvalumab significantly improved
progression-free and overall survival (PFS/OS), versus placebo, in patients with Stage III …
progression-free and overall survival (PFS/OS), versus placebo, in patients with Stage III …
[HTML][HTML] Final overall survival and safety update for durvalumab in third-or later-line advanced NSCLC: The phase II ATLANTIC study
MC Garassino, BC Cho, JH Kim, J Mazières… - Lung Cancer, 2020 - Elsevier
Introduction In the phase II ATLANTIC study, durvalumab provided durable responses with
acceptable tolerability in heavily pretreated patients with advanced NSCLC, across three …
acceptable tolerability in heavily pretreated patients with advanced NSCLC, across three …
The timing of durvalumab administration affects the risk of pneumonitis in patients with locally advanced non-small cell lung cancer: a systematic review and meta …
Z Yang, W Zhong, Y Luo, C Wu - BMC cancer, 2023 - Springer
Purpose The PACIFIC study has demonstrated that the administration of durvalumab
following concurrent chemoradiotherapy can significantly improve both overall survival and …
following concurrent chemoradiotherapy can significantly improve both overall survival and …
Baseline tumor size and survival outcomes in lung cancer patients treated with immune checkpoint inhibitors
AM Hopkins, G Kichenadasse, RA McKinnon… - Seminars in …, 2019 - Elsevier
Background Baseline tumor size (BTS) was recently indicated as prognostic of overall
survival (OS) in patients advanced melanoma treated with pembrolizumab. We review the …
survival (OS) in patients advanced melanoma treated with pembrolizumab. We review the …
Interferon gamma messenger RNA Signature in tumor biopsies predicts outcomes in patients with non–small cell lung carcinoma or urothelial cancer treated with …
BW Higgs, CA Morehouse, K Streicher… - Clinical Cancer …, 2018 - AACR
Purpose: To identify a predictive biomarker for durvalumab, an anti–programmed death
ligand 1 (PD-L1) mAb. Experimental Design: RNA sequencing of 97 advanced-stage non …
ligand 1 (PD-L1) mAb. Experimental Design: RNA sequencing of 97 advanced-stage non …
Real‐world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non–small cell lung cancer
Background Despite the rapid adoption of immunotherapies in advanced non–small cell
lung cancer (advNSCLC), knowledge gaps remain about their real‐world (rw) performance …
lung cancer (advNSCLC), knowledge gaps remain about their real‐world (rw) performance …
Durvalumab for the treatment of non-small cell lung cancer
L Mezquita, D Planchard - Expert Review of Respiratory Medicine, 2018 - Taylor & Francis
Introduction: In non-small cell lung cancer (NSCLC), immunotherapy is one of today's most
important and ground-breaking systemic treatments, mainly represented by antibodies …
important and ground-breaking systemic treatments, mainly represented by antibodies …
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
SJ Antonia, A Villegas, D Daniel… - … England Journal of …, 2017 - Mass Medical Soc
Background Most patients with locally advanced, unresectable, non–small-cell lung cancer
(NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy …
(NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy …
[HTML][HTML] Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics
L Mezquita, I Preeshagul, E Auclin, D Saravia… - European Journal of …, 2021 - Elsevier
Background dNLR at the baseline (B), defined by neutrophils/[leucocytes-neutrophils],
correlates with immune-checkpoint inhibitor (ICI) outcomes in advanced non–small-cell lung …
correlates with immune-checkpoint inhibitor (ICI) outcomes in advanced non–small-cell lung …